Podcast Episodes

Back to Search
Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival
Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival

Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!

1 day, 3 hours ago

Short Long
View Episode
Episode 528: ESMO 2026 - LITESPARK 012
Episode 528: ESMO 2026 - LITESPARK 012

Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annal…

1 day, 3 hours ago

Short Long
View Episode
Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer
Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer

Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.

1 day, 18 hours ago

Short Long
View Episode
Episode 526: ESMO 2026 - The VOLGA trial in MIBC
Episode 526: ESMO 2026 - The VOLGA trial in MIBC

Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.

1 day, 19 hours ago

Short Long
View Episode
Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281
Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281

Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC

1 day, 21 hours ago

Short Long
View Episode
Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC
Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC

Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to e…

1 day, 21 hours ago

Short Long
View Episode
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC

Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.

2 days, 21 hours ago

Short Long
View Episode
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized t…

2 days, 22 hours ago

Short Long
View Episode
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss …

2 days, 23 hours ago

Short Long
View Episode
Episode 520: ESMO 2026 Preview
Episode 520: ESMO 2026 Preview

Silke, Brian and Tom preview the major data to be presented at ESMO 2026

2 weeks ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us